Baseline characteristics
| Hospital death (n=21) | Hospital survival (n=166) | p Value | |
|---|---|---|---|
| Demographics | |||
| Age, mean±SD (years) | 66.8±18.23 | 55.7±15.0 | 0.002 |
| Male (n, %) | 10, 47.6 | 84, 50.6 | 0.821 |
| Race | |||
| Caucasian (n, %) | 10, 47.6 | 87, 52.4 | 0.767 |
| African-American (n, %) | 11, 52.4 | 77, 46.5 | |
| Other (n, %) | 0, 0 | 2, 1.2 | |
| Severity of illness | |||
| CURB 65 score, median | 4 | 2 | 0.025 |
| CURB score distribution (n, %) | – | ||
| 0 | 0, 0 | 28, 16.9 | |
| 1 | 2, 9.5 | 51, 30.7 | |
| 2 | 0, 0 | 28, 16.9 | |
| 3 | 6, 28.6 | 29, 17.5 | |
| 4 | 10, 47.6 | 25, 15.1 | |
| 5 | 3, 14.3 | 5, 3 | |
| ICU admission (n, %) | 5, 22.9 | 6, 3.6 | 0.001 |
| MV (n, %) | 6, 27.8 | 8, 4.8 | 0.001 |
| Comorbidities | |||
| LTC admission (n, %) | 2, 11.1 | 19, 11.4 | 0.999 |
| HD (n, %) | 0 | 4, 2.4 | 0.999 |
| Immunosuppression (n, %) | 7, 33.3 | 38, 22.9 | 0.289 |
| Prior antibiotics (n, %) | 7, 33.3 | 40, 24.1 | 0.423 |
| Recent hospitalisation (n, %) | 3, 14.1 | 15, 9.0 | 0.353 |
| Infection-related characteristics | |||
| Bacteraemia (n, %) | 3, 14.1 | 13, 7.8 | 0.256 |
| Delay in appropriate antibiotics (%)* | 8, 38.1 | 15, 9.0 | 0.001 |
| Antibiotic therapy | 0.099 | ||
| Ceftriaxone (n, %) | 7, 33.3 | 104, 62.7 | |
| Cefepime (n, %) | 8, 38.1 | 23, 13.9 | |
| Moxifloxacin (n, %) | 1, 4.8 | 21, 12.7 | |
| Piperacillin/tazobactam (n, %) | 2, 9.5 | 8, 4.8 | |
| Other (n, %) | 3, 14.3 | 10, 6.0 | |
| Any β-lactam/cephalosporin | 17, 81.0 | 135, 81.8 | 0.999 |
| Azithromycin | 5, 23.8 | 9, 5.4 | |
HD, haemodialysis; ICU, intensive care unit; LTC, long-term care; MV, mechanical ventilation.